DOP2007000091A - Uso de complejos metálicos que contienen perfluoroalquilo como medio de contraste para el diagnóstico de enfermedad de alzheimer - Google Patents

Uso de complejos metálicos que contienen perfluoroalquilo como medio de contraste para el diagnóstico de enfermedad de alzheimer

Info

Publication number
DOP2007000091A
DOP2007000091A DO2007000091A DO2007000091A DOP2007000091A DO P2007000091 A DOP2007000091 A DO P2007000091A DO 2007000091 A DO2007000091 A DO 2007000091A DO 2007000091 A DO2007000091 A DO 2007000091A DO P2007000091 A DOP2007000091 A DO P2007000091A
Authority
DO
Dominican Republic
Prior art keywords
metal complexes
complexes containing
perfluoroalquilo
alzheimer
disease diagnosis
Prior art date
Application number
DO2007000091A
Other languages
English (en)
Inventor
Bernd Misselwitz
Hanns-Joachim Weinmann
Joerg Meding
Original Assignee
Bayer Schering Pharma Ag
Epix Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Epix Pharm Inc filed Critical Bayer Schering Pharma Ag
Publication of DOP2007000091A publication Critical patent/DOP2007000091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere al uso de complejos metálicos que contienen al menos un radical alquilo perfluorado y al menos un radical de agente quelante y al menos un equiva-lente de ion metálico de los números atómicos 21-29, 31-33, 37-39, 42-44, 49 ó 57-83, así como sus sales para la pro-ducción de un agente diagnóstico para visualizar placas con contenido de amiloides.
DO2007000091A 2006-05-09 2007-05-08 Uso de complejos metálicos que contienen perfluoroalquilo como medio de contraste para el diagnóstico de enfermedad de alzheimer DOP2007000091A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006021495A DE102006021495A1 (de) 2006-05-09 2006-05-09 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit

Publications (1)

Publication Number Publication Date
DOP2007000091A true DOP2007000091A (es) 2008-01-31

Family

ID=38579874

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2007000091A DOP2007000091A (es) 2006-05-09 2007-05-08 Uso de complejos metálicos que contienen perfluoroalquilo como medio de contraste para el diagnóstico de enfermedad de alzheimer

Country Status (8)

Country Link
US (1) US20070269384A1 (es)
AR (1) AR064232A1 (es)
DE (1) DE102006021495A1 (es)
DO (1) DOP2007000091A (es)
PE (1) PE20081570A1 (es)
TW (1) TW200810782A (es)
UY (1) UY30332A1 (es)
WO (1) WO2007128567A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CA3120665A1 (en) 2018-11-23 2020-05-28 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19914101C1 (de) * 1999-03-22 2000-10-12 Schering Ag Perfluoralkylamide, ihre Herstellung und ihre Verwendung in der Diagnostik
DE10066210B4 (de) * 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
US6676928B2 (en) * 2000-08-11 2004-01-13 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use
US6818203B2 (en) * 2000-08-11 2004-11-16 Schering Aktiengesellschaft Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004064869A2 (en) * 2003-01-22 2004-08-05 The General Hospital Corporation Amyloid-binding, metal-chelating agents

Also Published As

Publication number Publication date
TW200810782A (en) 2008-03-01
UY30332A1 (es) 2008-01-02
DE102006021495A1 (de) 2007-11-15
US20070269384A1 (en) 2007-11-22
WO2007128567A1 (de) 2007-11-15
AR064232A1 (es) 2009-03-25
PE20081570A1 (es) 2009-01-04

Similar Documents

Publication Publication Date Title
AR047526A1 (es) Halogenoalquilcarboxamidas
UY30112A1 (es) Nuevos benzotiazoles sustitidos por heteroarilo
AR053334A1 (es) Pirazolilcarboxanilidas
CR20120264A (es) Compuestos
CL2011002287A1 (es) Compuestos derivados de 8-fenoxi-1,1-dioxido-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepina, moduladores de receptores ampa y nmda; composicion farmaceutica; procedimiento de prepapacion; y su uso para tratar enfermedades neurodegenerativas progresivas, alzheimer, parkinson, corea de huntington, entre otras; compuesto intermediario.
CR8879A (es) Bifeniltiazolcarboxamidas
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
UY28800A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparación y el uso de las mismas para combatir hongos nocivos
CO6351754A2 (es) Agentes de contraste que comprenden compuestos fenilo yodados
CY1111793T1 (el) Μυκητοκτονες συνθεσεις
UY31084A1 (es) Compuestos de azaindol para la inhibicion de b-secretasa
BRPI0518302A2 (pt) mÉtodo de formaÇço de imagens por rm
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
MA29539B1 (fr) Procedes de production de derives phenoliques 4-biphenylylazetidin -2-one
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
HN2008000088A (es) Heterociclicos de 1,4-dihidropiridina- fusionada, procesos para preparar los mismos, su uso y las composiciones que los contienen.
GT200600017A (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion, su uso como medicamento y medicamento que las comprende
DOP2007000091A (es) Uso de complejos metálicos que contienen perfluoroalquilo como medio de contraste para el diagnóstico de enfermedad de alzheimer
ES2653161T3 (es) Procedimiento de preparación de derivados de 3-alquilsulfinilbenzoílo
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.
TW200640467A (en) Compounds and uses thereof